DBV Technologies is set to announce its second quarter 2026 financial results and business update on July 16, 2026. The late-stage biopharmaceutical company will review its performance through a conference call and live audio webcast scheduled for 5:00 p.m. ET. This update will provide insights into the company's progress, particularly regarding its proprietary VIASKIN patch technology for food allergies.

Conference Call Details

Interested participants can join the call to discuss the Q2 2026 results using the following teleconferencing numbers:

A live webcast of the call will also be accessible via the Events section of the DBV Technologies website.

Business Focus

DBV Technologies specializes in developing treatment options for food allergies and other immunologic conditions. The company's primary focus is the VIASKIN Patch, which utilizes epicutaneous immunotherapy (EPIT) to introduce microgram amounts of biologically active compounds through the skin. The technology aims to re-educate the immune system to desensitize individuals to allergens.

Current clinical trials are underway for the VIASKIN Peanut Patch, targeting peanut-allergic toddlers (ages 1 to 3) and children (ages 4 to 7). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ.

DBV Technologies reported that its liquidity account held 146,321 shares and €396,088.22 as of June 30, 2026, marking an increase in share holdings compared to the 74,580 shares recorded on December 31, 2025. The liquidity contract, implemented with ODDO BHF, is designed to enhance the liquidity of DBV Technologies shares on the market in accordance with AMF Decision No. 2021-01 of June 22, 2021.

Liquidity Account Status

The assets in the liquidity account have fluctuated over the reporting period. When the contract was initially implemented on July 1, 2018, the account contained 41,159 shares and €432,367.25. By the end of 2025, the balance had grown to 74,580 shares and €527,891.63. As of the half-year mark in 2026, the share count increased significantly to 146,321, while the cash balance decreased to €396,088.22.

Trading Activity Overview

During the period from January 1, 2026, to June 30, 2026, the liquidity provider executed a total of 4,001 transactions. This included 1,989 buy transactions and 2,012 sales transactions. The trading activity resulted in a net purchase of 71,741 shares over the six months.

The total volume traded on the buy side amounted to 2,707,915 shares, valued at €8,836,273.65. On the sell side, the volume reached 2,636,174 shares, with a corresponding value of €8,704,457.81.

Transaction Summary (January 1, 2026 – June 30, 2026)

Regulatory Context

The liquidity contract operates under the framework established by the Autorité des Marchés Financiers (AMF). The agreement allows ODDO BHF to intervene in the market to ensure regular trading and liquidity for DBV Technologies shares, which are traded on Euronext Paris and the Nasdaq Capital Market.